Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Evogene Ltd. (EVGN : NSDQ)

• Company Description    Evogene is a leading computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. Incorporating a deep understanding of biology and leveraging Big Data and Artificial Intelligence, Evogene established its unique technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. Evogene holds a number of subsidiaries utilizing the CPB platform to develop human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. Number of Employees: 117

• Price / Volume Information    Yesterday's Closing Price: $0.85 Daily Weekly Monthly 20 Day Moving Average: 143,165 shares Shares Outstanding: 5.37 (millions) Market Capitalization: $4.54 (millions) Beta: 1.36 52 Week High: $2.42 52 Week Low: $0.73 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -4.69% 0.52% 12 Week -19.43% -14.16% Year To Date -23.09% -20.23%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 13 GAD FEINSTEIN STREET PARK REHOVOT - REHOVOT,L3 7638517 ISR ph: 972-8931-1900 fax: 972-8946-6724 rachel.pomerantz@evogene.com http://www.evogene.com

• General Corporate Information    Officers Ofer Haviv - Chief Executive Officer and President Nir Nimrodi - Chairperson of the Board Yaron Eldad - Chief Financial Officer Gabi Tarcic - Vice President Sarit Firon - Director Peer Information Evogene Ltd. (CORR.) Evogene Ltd. (RSPI) Evogene Ltd. (CGXP) Evogene Ltd. (BGEN) Evogene Ltd. (GTBP) Evogene Ltd. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: M4119S187 SIC: 2870 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/20/26 Share - Related Items Shares Outstanding: 5.37 Most Recent Split Date: 7.00 (0.10:1) Beta: 1.36 Market Capitalization: $4.54 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/20/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.38 Price/Cash Flow: - Price / Sales: 1.15 EPS Growth vs. Year Ago Period: -1,116.67% vs. Previous Quarter: -96.77% Sales Growth vs. Year Ago Period: -80.51% vs. Previous Quarter: 0.64% ROE 12/31/25 - -121.44 09/30/25 - -75.09 06/30/25 - -109.96 ROA 12/31/25 - -57.34 09/30/25 - -31.82 06/30/25 - -38.47 Current Ratio 12/31/25 - 4.54 09/30/25 - 5.11 06/30/25 - 1.89 Quick Ratio 12/31/25 - 4.48 09/30/25 - 4.59 06/30/25 - 1.76 Operating Margin 12/31/25 - -414.62 09/30/25 - -203.28 06/30/25 - -211.61 Net Margin 12/31/25 - -214.57 09/30/25 - -52.33 06/30/25 - -211.61 Pre-Tax Margin 12/31/25 - -350.32 09/30/25 - -231.31 06/30/25 - -240.01 Book Value 12/31/25 - 2.23 09/30/25 - 3.22 06/30/25 - 2.31 Inventory Turnover 12/31/25 - 2.55 09/30/25 - 1.44 06/30/25 - 2.05 Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©